Cited by 70Cardiac Imaging and DiagnosticsLipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Polypill Therapy, Subclinical Atherosclerosis, and Cardiovascular Events—Implications for the Use of Preventive Pharmacotherapy

Open access
Bittencourt, Márcio Sommer, Blaha, Michael J., Blankstein, Ron, Budoff, Matthew, Vargas, Jose D., Blumenthal, Roger S., Agatston, Arthur S., Nasir, Khurram·2014·Journal of the American College of Cardiology

Abstract

Objectives This study examines whether the coronary artery calcium (CAC) score can be used to define the target population to treat with a polypill.Background Prior studies have suggested a single polypill to reduce cardiovascular disease (CVD) at the population level.Methods Participants from MESA (Multi-Ethnic Study of Atherosclerosis) were stratified using the criteria of 4 polypill studies (TIPS [The Indian Polycap Study], Poly-Iran, Wald, and the PILL [Program to Improve Life and Longevity] Collaboration). We compared coronary heart disease (CHD) and CVD event rates and calculated the 5-year number needed to treat (NNT) after stratification based on the CAC score.Results Among MESA participants eligible for TIPS, Poly-Iran, Wald, and the PILL Collaboration, CAC = 0 was observed in 58.6%, 54.5%, 38.9%, and 40.8%, respectively. The rate of CHD events among those with CAC = 0 varied from 1.2 to 1.9 events per 1,000 person-years, those with CAC scores from 1 to 100 had event rates ranging from 4.1 to 5.5, and in those with CAC scores >100 the event rate ranged from 11.6 to 13.3. The estimated 5-year NNT to prevent 1 CVD event ranged from 81-130 for patients with CAC = 0, 38-54 for those with CAC scores from 1 to 100, and 18-20 for those with CAC scores >100.Conclusions In MESA, among individuals eligible for treatment with the polypill, the majority of CHD and CVD events occurred in those with CAC scores >100. The group with CAC = 0 had a very low event rate and a high projected NNT. The avoidance of treatment in individuals with CAC = 0 could allow for significant reductions in the population considered for treatment, with a more selective use of the polypill and, as a result, avoidance of treatment in those who are unlikely to benefit.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.08.1640

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bittencourt, M. S., Blaha, M. J., Blankstein, R., Budoff, M., Vargas, J. D., Blumenthal, R. S., Agatston, A. S., & Nasir, K.
Affiliations
  • Brigham and Women's Hospital (US)
  • Johns Hopkins University (US)
  • University of California, Los Angeles (US)
  • National Institutes of Health (US)
  • Baptist Hospital of Miami (US)
Corresponding author
Nasir, Khurram
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2014-02
Volume
63
Issue
5
Pages
434-443
ISSN
0735-1097 (ISSN-L)
OpenAlex
W1844872504
Cited by
70
References
31
Citations by year
2025: 4 · 2024: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 11 · 2016: 12 · 2015: 13 · 2014: 9 · 2013: 3
FWCI
9.55
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR001079)
  • National Heart, Lung, and Blood Institute (L30HL110027)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
polypill, coronary artery calcium, subclinical atherosclerosis, cardiovascular disease prevention, coronary artery disease, number needed to treat, target population selection, Multi-Ethnic Study of Atherosclerosis
MeSH terms
Adult, Aged, Aged, 80 and over, Calcinosis, Calcium, Coronary Artery Disease, Coronary Vessels, Drug Therapy, Combination, Ethnicity, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Time Factors, Tomography, X-Ray Computed, United States, Incidence, Prevalence, Coronary Angiography, Risk Assessment, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review